Table 2.
Levels of 24 h UFC before and after dexamethasone
| Group | PPNAD | BMAH | ADA | P-value |
|---|---|---|---|---|
| Baseline (µg/d) | 383.50 (271.61, 452.97) # | 314.70 (151.04, 557.16) | 224.42 (144.50, 334.88) | 0.002 |
| LDDST (µg/d) | 497.35 (389.86, 717.70) # | 325.60 (124.28, 557.03) | 181.66 (108.00, 252.00) $ | 0.000 |
| HDDST (µg/d) | 495.30 (402.97, 876.55) # | 339.84 (175.42, 526.13) * | 184.50 (116.20, 309.61) | 0.000 |
| Post/Pre (L) | 1.29 (0.91, 1.71) # | 0.93 (0.82, 1.23) | 0.78 (0.51, 1.07) | 0.000 |
| Post/Pre (H) | 1.48 (1.14, 2.09) # | 0.94 (0.76, 1.59) * | 0.92 (0.71, 1.07) | 0.000 |
PPNAD pigmented nodular adrenocortical disease, BMAH bilateral macronodular adrenal hyperplasia, ADA adrenocortical adenoma, LDDST low-dose dexamethasone suppression test, HDDST high-dose dexamethasone suppression test, Post/Pre (L) the ratio of 24 h UFC posterior to LDDST and prior to LDDST, Post/Pre (H) the ratio of 24 h UFC posterior to HDDST and prior to HDDST
* PPNAD vs. BMAH, P < 0.017; # PPNAD vs. ADA, P < 0.017; $ BMAH vs. ADA, P < 0.017